UniProtKB/Swiss-Prot P68871 : Variant p.Ser50Phe
Hemoglobin subunit beta
Gene: HBB
Feedback ?
Variant information
Variant position:
50
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Serine (S) to Phenylalanine (F) at position 50 (S50F, p.Ser50Phe).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and polar (S) to large size and aromatic (F)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Polymorphism:
Genetic variations in HBB are involved in resistance to malaria [MIM:611162 ]. Hemoglobin S (Hb S), which at homozygosity is responsible for sickle cell anemia, is not associated with any clinical abnormality when heterozygous. At heterozygosity, Hb S confers an increase in protection from life-threatening malaria. Additional variants conferring resistance against severe malaria are hemoglobin C (Hb C) and hemoglobin E (Hb E).
Additional information on the polymorphism described.
Variant description:
In Las Palmas; slightly unstable.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
50
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
147
The length of the canonical sequence.
Location on the sequence:
GRLLVVYPWTQRFFESFGDL
S TPDAVMGNPKVKAHGKKVLG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 147
Hemoglobin subunit beta
Domain
3 – 147
Globin
Binding site
64 – 64
distal binding residue
Site
60 – 60
Not glycated
Modified residue
45 – 45
Phosphoserine
Modified residue
51 – 51
Phosphothreonine
Modified residue
60 – 60
N6-acetyllysine
Glycosylation
67 – 67
N-linked (Glc) (glycation) lysine
Literature citations
The differently expressed genes in the lymphocyte of recovered SARS patients.
Fan B.; Xie L.; Guan X.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS PHE-50 AND PRO-76;
Hb Las Palmas or alpha 2 beta 2(49)(CD8)Ser-->Phe, a mildly unstable hemoglobin variant.
Malcorra-Azpiazu J.J.; Balda-Aguirre M.I.; Diaz-Chico J.C.; Hu H.; Wilson J.B.; Webber B.B.; Kutlar F.; Kutlar A.; Huisman T.H.J.;
Hemoglobin 12:163-170(1988)
Cited for: VARIANT LAS PALMAS PHE-50;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.